Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ:WALD) ("Waldencast" or the "Company"), today announced VIO Med Spa as a launch partner for the Aesthetics Leadership with Obagi's Hyaluronic Acid (ALOHA) Program. VIO Med Spa was selected for its rapid growth, expert-led approach to advanced aesthetic treatments, and dedication to delivering high-quality, results-driven care across its expanding national network of locations.

Through this real-world evaluation collaboration, VIO Med Spa will conduct a structured, multi-site assessment of Obagi® saypha® MagIQ™ across its practices. The program will leverage VIO Med Spa's strengths in innovative injectables, personalized wellness protocols, and patient-focused education to generate robust real-world evidence on the filler's performance in diverse, high-volume aesthetic environments.